This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk02: Good afternoon, ladies and gentlemen, and welcome to the Capricorn Therapeutics second quarter 2023 financial results and corporate update call. At this time, all lines are in a listen-only mode. Following the presentation, we will conduct a question and answer session. If at any time during this call you require immediate assistance, please press star zero for the operator. As a reminder, this conference call is being recorded. I would now like to turn the conference over to our host, Mr. A.J. Bergman, Capicor's Chief Financial Officer.
spk06: Thank you, and good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today's presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our future research and development plans, including our anticipated conduct and timing of preclinical and clinical studies, plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments regarding our product candidates, manufacturing capabilities, potential milestone payments, and other possible uses of existing cash and investment resources. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change and involve a number of risks and uncertainties and may cause actual results to differ materially from those contained in the forward-looking statements. These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements. With that, I'll turn the call over to Linda Marban, CEO.
spk03: Thank you, AJ. Good afternoon, and thank you for joining our second quarter 2023 conference call. Today, I would like to begin by reiterating our deep commitment to optimizing patient focused medicine and in the first half of 2023, we continue to make steady progress across our pipeline and are well positioned to deliver on important clinical and regulatory milestones for our Duchenne muscular dystrophy program, as well as continue to advance our Exosome platform technology. I am extremely pleased with the recent additions of two new members to our Board of Directors with the additions of Drs. Philip Gottwald and Paul Atwater. Dr. Gottwald most recently served as the Global Head Vice President of Business Development and Licensing at Novartis Institutes for Biomedical Research and has nearly 30 years of experience in drug development, research, corporate strategy, and business development. Dr. Atwater brings over 30 years of internal medicine and infectious disease experience as the Sherilyn and Ken Fisher Professor of Medicine at the Johns Hopkins University School of Medicine, serving as the Clinical Director for the Division of Infectious Diseases and the Director of the Sherilyn and Ken Fisher Center for Environmental Infectious Diseases. Both Dr. Gottwald and Atwater's deep industry experience will be invaluable as we continue to enhance our strategic and business development priorities across both of our programs. Our late stage clinical development program for CAP 1002 and patients with DMD continues to advance through development and key priorities, including enrollment of our phase three, hope three clinical trials, which I will give more details on in the next few minutes, as well as continuing discussions with the FDA regarding the proposed path towards submissions of a biologics license application. Building on this momentum, we believe we are well positioned to execute our corporate objectives throughout the remainder of the year. I will now dive into our programs and provide an update on recent activity. Let me provide you an update on our recent FDA interactions. Earlier this year, As part of our RMAT designation, we held a Type B CMC, or Chemistry, Manufacturing, and Controls-related meeting with FDA, where we outlined our plans for production of commercial-scale GMP Cap 10-02. The outcome of this meeting was positive in that FDA clearly outlined for us the deliverables necessary for the CMC portion of our BLA. As we previously have reported, there also was a discussion concerning the possible inclusion of additional patients who would need to be treated with product from our San Diego GMP facility in order to support commercial product manufacturing at this site. As this request would have likely extended the timeline for the completion of our pivotal trial and therefore the time to BLA, we requested a subsequent Type B clinical meeting with FDA to determine if there was a more efficient and expeditious path to BLA due to the great unmet medical need of this patient population. The advocacy community believes, as we do, that CAP 1002 attenuates disease progression and they have continued to raise awareness of our program within the FDA, and specifically CBER, and as the FDA continues to highlight the importance of patient perspective, they have continued to pay close attention to our program. To that end, the FDA granted our request to discuss our program in more detail, and this meeting occurred in July of this year. The goal was to further outline a plan for an expedited path to BLA for Cap 1002 for the treatment of later stage DMD. And I am happy to share that FDA seemed generally supportive of this plan. Currently, we are awaiting the final minutes from FDA, which we expect this month. We have already had another informal meeting with FDA to further define certain aspects of our program, and we are greatly appreciative of the FDA's guidance to optimize the HOPE III clinical trial design to support our path to potential approval. Next, I will provide an update on HOPE III, our Phase III clinical trial. I am very pleased to inform you that as of today, we have randomized 48 subjects across 17 active sites, and based on the currently designed sample size of 68 patients, we are on track to be fully enrolled early in the fourth quarter of this year. Furthermore, we remain on track to conduct an interim analysis on HOPE III in the fourth quarter of this year, which will primarily focus on a futility analysis. I am very enthusiastic about the rate of enrollment, which has been strong throughout the summer, and propelled by the positive feedback from patients and families, including the anecdotal reports of disease attenuation. Additionally, we are extremely pleased by the safety profile of CAP 1002 and the overall support of our investigators and families. Now, for an update on our most recent hope to open label extension or results presented at this year's parent project for muscular dystrophy annual conference. To remind you, we presented positive statistically significant two year follow up results from the study. As you may recall the hope to study. previously met its primary endpoint at the one-year time point on the pull version 2.0 scale. At the 24-month time point, the data continued to show statistically significant differences in the pull performance of the upper limb version 2.0 in the open label extension treatment group when compared to the original rate of decline of the placebo group from HOPE-2 after one year. Even more profound were the cardiac findings we observed. While the natural history of DMD cardiomyopathy suggests a steady decline in cardiac function as measured by ejection fraction, in HOPE2-OLE, we observed improvements in heart function in six of nine patients. Over time, we also observed an increase in correlation with the performance of the upper limb version 2.0 and ejection fraction results. The two-year results from this open-label study are tremendously impactful for DMD patients, showing cardiac and skeletal functional benefits, which underscores the potential long-term benefits of CAP-1002 treatment in DMD. The disease-modifying potential, together with the favorable safety and tolerability profile, further positions CAP-1002 as a potential anchor therapy for DMD patients. We are thankful. to the patients and their families for their continuous commitment to working with us on demonstrating the potential benefits of CAB 1002. Now, turning to our partnership strategy. Now that we have secured commercial and distribution rights in the US and Japan with our partner Nippon Shinnyaku, we continue to focus on securing additional partners in other markets around the world, with Europe being a key priority. and now have several companies evaluating the opportunity. Another focus I would like to briefly touch upon is the opportunity to evaluate new indications where CAP 1002 might provide benefits to additional patients. While we haven't committed any resources to this development area yet, this opportunity would provide another potential avenue for partnering, licensing, or even sole development leveraging on the capabilities we have built at Capricor for CAP 1002. Lastly, I would like to provide on our update on our GMP manufacturing facility. We have designed this GMP manufacturing facility to produce commercial-scale GMP CAP 1002 doses. We see this facility as a versatile and cost-effective way to bring CAP 1002 to market efficiently. In anticipation of CAP 1002 obtaining market approval, we built this facility because we believe having the ability to manufacture in-house will greatly increase our margins and will support the early launch of this product. I am pleased to report that the San Diego facility is up and running, engineering runs are underway, and we remain on track to be able to release clinical doses in the third quarter of this year. Overall, I am very pleased with the progress of our DMD program. We look forward to sharing further updates from our interactions with FDA, our progress with HOKE III, and the development of potential additional partnerships in new territories. We have two new additions to our senior leadership team, enhancing our regulatory and CMC internal expertise. Dr. Yuxi Feng has assumed his role as vice president of regulatory, overseeing all regulatory activities. Dr. Feng previously worked at the FDA, wave life sciences, and Kodiak Biosciences. Each of these companies have overlapping areas with overlap are overlapping with our areas of focus. Additionally, Jonathan Takeo has joined us as vice president of program management and business operations overseeing CMC development. Prior experience for Mr. Tako included Kite Pharma, where he played an integral role in the BLA approval of Yescarta, one of the first approved cell therapy treatments for large B-cell lymphoma. I am very pleased to welcome these two new members to our team. Now, turning to our ExaZone platform technology, which leverages the natural cell-to-cell communication of the body. We are harnessing exosomes to serve as a novel drug delivery system with broad therapeutic applications, and our proprietary StealthX expression platform is at the core of our exosome program, which is focused on the development of two broad modalities, infectious disease and precision therapeutic. As previously stated, we believe that exosomes are the future of drug delivery. They are able to deliver contents directly to the cell, avoid detection by the immune system, and can be targeted. However, one of the issues that the field has been grappling with is the ability to manufacture a large volume of a relatively homogeneous formulation similar to lipid nanoparticles. We have focused a significant amount of time and energy into manufacturing and targeting of exosomes, and I am delighted to share with you that we have made paradigm-shifting progress on these objectives. This development step allows for rapid and efficient development of future exosome products. To that end, I'm very pleased to report that we have recently begun work with an undisclosed pharma company looking at enhancing delivery of ASOs using exosomes as the delivery vehicle. I look forward to providing more details on this in the coming months as this is a very important step for Capricorn as we begin to leverage our platform StealthX. We look further to exploring the applications of our StealthX platform as we expand into a precision-based therapeutic and are working in targets primarily in neuromuscular diseases at this time. Additionally, we recently published data in BioRxiv, a journal featuring two vaccine candidates that were generated with StealthX. Exosomes were engineered to express influenza H3 or SARS-CoV-2 spikes. When administered individually, both StealthX H3 and StealthX Spike introduced a strong immunization with the production of a potent humoral and cellular immune response. These effects were obtained with administration of nanograms of protein and without adjuvant or lipid nanoparticles. To test the potential benefits of the bivalve vaccine, hemagglutinin H3 and SARS-CoV-2 spike proteins were individually engineered on the exosome surface and mixed before injection. This combination approach also induced a strong immune response in mice with both antibody and T-cell response. Additionally, there were no detectable immune competition between antigens. By combining multiple targets in a single vaccine formulation, these results support the potential therapeutic utility and versatility of our StealthX platform and addressing a broad range of infectious diseases. Our current plans continue to focus on leveraging business development and partnering strategies, as well as non-dilutive grant funding for our Exosome platform technology. In closing, we are pleased with the advancements across our organization, as we remain focused on becoming a commercial-scale company with CAP-1002 as our lead asset and development of our Exosome technology. We are entering the second half of the year in a position of strength. I look forward to working with our new board members and capitalizing on their deep industry experience and forward-looking vision, which we feel will be invaluable as we continue to execute on the key priorities for CAP 1002 and our ExaZone platform. Now, with that, I will turn the call over to our Chief Financial Officer, A.J. Bergman, to run through our financial results for the second quarter of 2023. Thank you, Linda.
spk06: This afternoon's press release provided a summary of our second quarter 2023 financials on a GAAP basis. You may also refer to our quarterly report on Form 10-Q, which we expect to become available shortly and will be accessible on the SEC website as well as the financial section of our website. As of June 30, 2023, the company's cash, cash equivalents, and marketable securities totaled approximately $37.8 million compared to approximately $41.4 million on December 31, 2022. Based on our current operating plan, the company's cash position is expected to be sufficient to support operations through the third quarter of 2024. I would like to note that this expectation excludes any additional potential milestone payments under our exclusive commercialization and distribution agreements with Nippon Shinnyaku that may become due, which would extend our cash runway. Turning to the financials. Revenues for the second quarter of 2023 were approximately $3.9 million, compared with zero for the second quarter of 2022. The primary source of revenue was from the ratable recognition of the $30 million upfront payment in accordance with our U.S. exclusive commercialization and distribution agreement we received from Nippon Shin'yaku. Moving to our operating expenses for the second quarter of 2023, excluding stock-based compensation, our research and development expense was approximately $8.4 million compared to approximately $4.7 million in Q2 2022. Again, excluding stock-based compensation, our general and administrative expenses were approximately $1.7 million in Q2 2023 and approximately $1.4 million in Q2 2022. Net loss for the second quarter of 2023 was approximately $7.4 million compared to a net loss of approximately $7.1 million for the second quarter of 2022. Net loss for the first half of 2023 was approximately $15.1 million compared to a net loss of approximately $14.9 million for the first half of 2022. And with that, we will now open the line up for questions. Thank you very much.
spk02: Thank you, sir. Ladies and gentlemen, we will now begin the question and answer session. Should you have a question, please press star followed by the number one on your touchstone phone. Again, that's star followed by the number one. If you would like to withdraw your request, please press star followed by the number two. Your first question comes from the line of Joe Pantginas from HC Wainwright. Please go ahead.
spk05: Hi, good afternoon, Linda and AJ. Thanks for taking the questions. So I know there's a lot of working parts here, and I know my questions will revolve around some things that you might not be able to detail because the FDA minutes are not out yet, but I'm still going to ask them. So with that said, I guess as San Diego comes online this quarter, if I heard you correctly, do you have a general range of the number of patients that would be required from that facility to start with?
spk03: Yeah, Joe. Hey, good to talk to you. And you're correct. There's very little we can say until we get the final minutes. But what I can tell you is that once we get them, we plan on doing a public release in some way, either via press release and or a call to sort of update the market and the community as to exactly the path forward. What I can tell you is that FDA has worked really closely with us. They're very supportive of this program. Several of our patients' families have reached out to FDA in order to ask them to take a really careful look at Capricorn, help move the program forward because they feel that their sons are feeling and functioning better. And so we're confident that the answers that we get back from FDA will be the best ones possible to move the product towards BLA.
spk05: That makes sense. And I guess for my next question, it's sort of in the same realm, but I'll ask it sort of scenario-based. So you do have the minutes that you're awaiting right now. You also have the upcoming interim analysis in the fourth quarter for HOPE III, which you said is primarily based on putility. However, does one of the potential scenarios include the positive feedback from the minutes with regard to the data you might see in the interim that could allow for the acceleration or resetting of the timelines positively for HOPE III?
spk03: Yeah, that was a pretty impressive question to ask, Joe. Good work. I can tell you've been doing this a long time. So, the answer to that is, futility is the metric that we're looking at for the interim analysis. FDA has been pretty clear with us that they want to keep this trial Very tightly regulated, really carefully monitored because they believe in the product, too. We can tell from their feedback for us. And so we're probably not going to use the interim for accelerated approval opportunity. I can tell you that I am laser focusing on opportunities where we may be able to take advantage of an earlier look to look for an accelerated approval. I cannot disclose now how we might do that, but that is something we're definitely thinking about.
spk05: Got it. And I guess my other questions are strictly logistical. So in the conduct of HOPE III, you're obviously encouraged by the enrollment rates that you've been seeing, if I understand correctly. What are the prominent reasons for screening failure of patients, and also what does the patient pipeline look like for potential enrollments?
spk03: Yeah, Joe, great, great question. So screen failure, which is really come down a lot thanks to our really very strong new clinical team that we put in place. And the primary reasons that people fail out typically is that they don't have inclusion criteria of the performance of the upper limb score two to five. And so we typically see some of these guys whose scores are too low. And let me just say from a human level, it's heartbreaking because they have to have the ability to use their hands and bring it to their mouth unassisted. And we probably get two or three calls a week from people saying, well, you know, what if they need help? What if they use their other hand to boost it? People want CAP-1002 desperately. So that leads into the answer to your second question. The pipeline of potential patients is very rich. There's a lot of energy around this open-label extension data. At the PPMD meeting, we were by far one of the busiest booths, you know, second only to Sarepta with the gene therapy. And so, we are looking to build with Sarepta with all of the gene therapies that could come along as anchor therapy for CAP-1002. And so, the families see it that way as well. So, we do not see any potential turndown or downturn, not downturn, downturn in patient opportunities moving forward.
spk05: Got it. And then lastly, going away from HOPE III and DMD, you did give us a little bit of a tease again about additional CAP 1002 opportunities. And I was just curious here, any potential for going back to any of the prior indications that you've worked on in the cardiovascular arena or any teasing you might want to give us now with regard to newer indications? Or is this a wait and see?
spk03: Yeah, so I think the best way to answer that is we are very pleased with the progress of cap 10 or 2 and DMG. I think it's very clear that there seems to be a disease modifying and a very strong treatment effect that persists after years. Our patients have done really well on a repeated exposure. open label extension patients that are in their third year and coming into their fourth year of treatment and so it's very safe the infusions are easy so we are opening the door internally to look at potential opportunities for cap 1002 we're exploring those now and we'll provide updates as we have them to where we will likely deploy CAP-1002 next. But what I can tell you, you know, if you're sort of looking into your crystal ball, you know, we've seen really nice data in an inflammatory cardiomyopathy, skeletal muscle disease, neuromuscular disease. We know that, you know, CAP-1002's primary mode of action is immunomodulatory and pro-regenerative. So we're going to continue to explore indications that the disease pathogenesis would be highlighted by those two processes.
spk05: Got it. Thank you, Linda. Appreciate it.
spk01: Thanks, Joe. Take good care. I'll see you soon.
spk02: Ladies and gentlemen, just a reminder, if you have a question, please press star followed by the number one on your touchstone phone. Your next question comes from the line of Alan Leong from BioWatch News. Please go ahead.
spk04: Linda, AJ, it's great to be back. And what wonderful commentary, Linda, your commentary, uh, It spins way beyond the release and love to hear it. And also a shout out to Joe, the last analyst, for a great question. I have a couple sets of questions. You are into really low volume, high margin products, although Linda, you taught my ear about the breakthrough into scalability. Is the pilot manufacturing model a possible template for Capricor's future path towards vertical integration. In other words, are you considering this your usual modus operandi going forward? You could simply replicate pilot-sized facilities. Your products seem to be in that sweet spot. I wonder if you could provide any commentary on that.
spk03: Are you talking, Alan? By the way, it's great to hear your voice, and I hope you're continuing to do well. But are you talking primarily about exosomes or CAP-1002 in terms of pilot manufacturing expansions?
spk04: Both. If I understand the manufacturing, you don't need a large footprint for either to accomplish what you need.
spk03: Right. So they're similar but different, obviously. So with CAP 1002, we really have put several manufacturing scale out and scale up opportunities in place so that we can reduce the footprint necessary and create more self. That's been pretty effective, and that's largely been the focus of the transfer to the San Diego GMP facility. We're working really closely with FDA and their CMC group in order to make sure that the product is the same as we produce in the pilot facility, which is why we're working right now to get those out there and into the clinic. So, yes, we expect that we could expand this. And it won't exactly be as I think you're envisioning, which is we take 10 little pilot facilities and turn it into 100 little pilot facilities. It'll be an expanded facility, but the manufacturing processes will be largely the same. You know, cell therapy manufacturing opportunities has really expanded in the past couple decades. So there's a lot of good opportunity there. So not exactly how you envisioned, but almost. In terms of exosomes, that is one of the areas of great pride for us. As I mentioned in my prepared remarks, you know, one of the things that have held back exosomes is how are you going to make these? How are you going to make them homogeneous? How are you going to turn them into a product? And we believe that we have done that. We have taken sort of the state-of-the-art and what is known about exosomes, making lipid nanoparticles as well as some of the other engineering constructs and are building a really good manufacturing paradigm that also should be buildable and not really pilot plant expansion. That one will be more like, you know, big bubbling bioreactors and that kind of thing as we move it forward. But that's a procedure that can easily go from, you know, a couple mils to 100 mils to liters, you know, and to larger volumes than that. That makes any sends to you, Alex.
spk04: It does. You know, you also caught my ear about the ASO undisclosed pharma interest. I want to go more general. Can I get more commentary on the general pharma and suitor interest? Because I've been watching this. How much pursuit from suitors or combination trials? Because if I read some of the literature, right, if I'm wrong, feel free to bat me on the head. There's been serious absorption issues of the current gene and cell therapies. This is where TAP1002 potentially becomes 1 plus 1 equals 3 and not 2. There's a lot of interest from those who are in that space. Can you further comment on that in general?
spk03: You mean with the exosomes in terms of their partnering potential?
spk01: Yes.
spk03: Yeah, absolutely. You know, this is one of the great opportunities in biotechnology, and pharma is well aware of it. I think everybody knows that lipid nanoparticles can only take you so far. We've been working as a field, and I say we because this even predates my own career in science on, you know, delivery and targeted delivery of therapeutics to cells. We know how important that is. and we can now harness something that the body makes naturally to do that. And so that's why Capricor has really turned our focus in the past few years towards an engineered exosome platform, not working specifically with an exosome made by a cell. CAP-1002 makes perfectly wonderful exosomes. They mediate the mechanism of action of CAP-10-2. But what we really want to do is turn exosomes into a drug product. And so you engineer an exosome, you put what you want on the inside, and you tell it where to go on the outside. It's like putting a zip code on it. And, of course, pharma is very interested in that. And we have a very active business development program right now. And one of the main hurdles was this manufacturing step, which we have succeeded in doing. So we look forward to great opportunities with the exosomes moving forward.
spk04: Last question, but this is for AJ. I guess for both of you, this will be a fun question, but it does get to some interesting things. You got $10 million more up front cash from the last agreement. You got a grant or another agreement that brings in another $10 million. How would you like it used?
spk01: Yeah, thanks, Alan.
spk06: Nice to hear from you. I mean, obviously, bringing in non-dilutive capital is a big focus for us, as you heard Linda articulate, both from potential in our approach to vaccinology, as well as the next steps, which is targeted therapeutics. Where exactly would we like to deploy it? I mean, if I had my wish list, it would be great to use that non-dilutive capital to move into these types of new indications that we're hinting at here, whether it's new neuromuscular targets or potentially using the exosome as a targeted vehicle. That would be my wish list. And Taking those non-dilutive capital dollars in the door is a big area that we're putting a lot of energy in. I don't know if Linda wants to articulate anything else.
spk03: Yeah. So, you know, cash is king as you are in product development mode. And so, you know, what we would definitely do is use it in a laser-focused, targeted way to move our programs forward. So CapTender 2 is at the front of the line right now. all, you know, major dollars being spent or being spent on getting, you know, CAP TETA 2 approved, and then the few, you know, dollars left over go towards the Exosome program as we move that forward. If the dollars come in and are specifically requested to build a program, we would obviously work on that. there was a deal where they wanted to build an engineered exosome. That's where a good proportion of those dollars would go. So to that end, we are focusing on what we need to do. AJ maintains a very tight ship in terms of managing our resources. And that explains why we've been able to stay alive through some pretty difficult times.
spk04: Well, I look forward in the immediate future, Linda, to walk into your office. The future looks bright for both of us. Oh, that's wonderful news.
spk03: That's wonderful news. Well, the future is bright for Capricorn, but if the future is bright for you, that's great news, Alan. So let's see each other soon.
spk04: Thank you.
spk01: Looking forward to it. All right. Take care, Alan. Take care.
spk02: Ladies and gentlemen, just a reminder, should you have a question, please press star followed by the number one on your touchstone phone. There seems to be no further questions at this time. I'd now like to turn the call back over to Capicor Management for any closing remarks.
spk03: Thank you. Overall, I am confident that the company's upcoming catalysts provide a solid foundation for execution and value creation. We remain focused on driving our late stage clinical development program forward for cap ten or two and DMD before we conclude today's call. I want to extend my sincere appreciation to the clinicians patients and their families who are working with us to bring cap ten or two closer to potential approval again. Thanks to everyone who joined us this afternoon and now you may disconnect your line.
Disclaimer